**Stephen Senn **

Consultant Statistician

Edinburgh, Scotland

# The usual warning

Although I have researched on clinical trial design for many years, prior to the COVID-19 epidemic I had had nothing to do with vaccines. The only object of these amateur musings is to amuse amateurs by raising some issues I have pondered and found interesting.

# Coverage matters

In this blog I am going to cover the statistical analysis used by Pfizer/BioNTech (hereafter referred to as P&B) in their big phase III trial of a vaccine for COVID-19. I considered this in some previous posts, in particular Heard Immunity, and Infectious Enthusiasm. The first of these posts compared the P&N trial to two others, a trial run by Moderna and another by Astra Zeneca and Oxford University (hereafter referred to as AZ&Ox) and the second discussed the results that P&N reported.

*Figure 1 Stopping boundaries for three trials. Labels are anticipated numbers of cases at the looks.*

All three trials were sequential in nature and, as is only proper, all three protocols gave details of the proposed stopping boundaries. These are given in Figure 1. AZ&Ox proposed to have two looks, Moderna to have three and P&B to have five. As things turned out, there was only one interim look at the P&B trial and so two, and not five, in total.

Moderna and AZ&Ox specified a frequentist approach in their protocols and P&B a Bayesian one. It is aspects of this Bayesian approach that I propose to consider.

# Some symbol stuff

It is common to measure vaccine efficacy in terms of a relative risk reduction expressed as a percentage. The percentage is a nuisance and instead I shall express it as a simple ratio. If *ψ*, *π _{c}*,

*π*are the

_{v}*true*vaccine efficacy and the probabilities of being infected in the control and vaccine groups respectively, then

Note that if we have *Y _{c}, Y_{v }*cases in the control and vaccine arms respectively and

*n*subjects then an intuitively reasonable estimate of

_{c}, n_{v }*ψ*is

where VE is the *observed* vaccine efficacy.

If the total number of subjects is *N* and we have *n _{c} = rN, n_{v}_{ }*= (1 −

*r*)

*N*, with

*r*being the proportion of subjects on the control arm, then we have

Note that if *r* = 1 − *r* = 1/2, that is to say that there are equal numbers of subjects on both arms, then (3) simply reduces to one minus the ratio of observed cases. *VE* thus has the curious property that its maximum value is 1 (when there are no cases in the vaccine group) but its minimum value is −∞ (when there are no cases in the control group and at least one in the vaccine group).

A contour plot of vaccine efficacy as a function of the control and vaccine group probabilities of infection is given in Figure 2.

*Figure 2 Vaccine efficacy as a function of the probability of infection in the control and vaccine groups.*

# Scaly beta

P&B specified a prior distribution for their analysis but very sensibly shied away from attempting to do one for vaccine efficacy directly. Instead, they considered a transformation, or re-scaling, of the parameter defining

This looks rather strange but in fact it can be re-expressed as

*Figure 3 Contour plot of transformed vaccine efficacy, θ.*

Its contour plot is given in Figure 3. The transformation is the ratio of the probability of infection in the vaccine group to the sum of the probabilities in the two groups. It thus takes on a value between 0 and 1 and this in turn implies that it behaves like a probability. In fact if we have equal numbers of subjects on both arms and condition on the total numbers of cases we can regard it as being the probability that a randomly chosen case will be in the vaccine group and therefore as an estimate of the efficacy of the vaccine. The lower this probability, the more effective the vaccine.

In fact, this simple analysis, captures much of what the data have to tell and in estimating vaccine efficacy in previous posts. I simply used this ratio as a probability and estimated ‘exact’ confidence intervals using the binomial distribution. Having calculated the intervals on this scale, I back-transformed them to the vaccine efficacy scale

A prior distribution that is commonly used for modelling data using the binomial distribution is the beta-distribution (see pp. 55-61 of Forbes et al[1], 2011), hence the title of this post. This is a two parameter distribution with parameters (say) ν, ω and mean

and variance

Thus, the relative value of the two parameters governs the mean and, the larger the parameter values, the smaller the variance. A special case of the beta distribution is the uniform distribution, which can be obtained by setting both parameter values to 1. The resulting mean is 1/2 and the variance is 1/12. Parameter values of ½ and ½ give a distribution with the same mean but a larger variance of 1/8. For comparison, the mean and variance of a binomial proportion are *p, p*(1 − *p*)/*n *and if you set *p *= 1/2, *n* = 2 you get the same mean and variance. This gives a feel for how much information is contained in a prior distribution.

# Of Ps and Qs

P&B chose a beta distribution for θ with ν = 0.700102, ω = 1. The prior distribution is plotted in Figure 4. This has a mean of 0.4118 and a variance of approximately 1/11. I now propose to discuss and speculate how these values were arrived at. I come to a rather cynical conclusion and before I give you my reasoning, I want to make two points quite clear:

a) My cynicism does not detract from my admiration for what P&B have done. I think the achievement is magnificent, not only in terms of the basic science but also in terms of trial design, management and delivery.

b) I am not criticising the choice of a Bayesian analysis. In fact, I found that rather interesting.

However, I think it is appropriate to establish what exactly is incorporated in any prior distribution and that is what I propose to do.

First note the extraordinary number of significant figures (6) for the first parameter, of the beta distribution, which has a value of 0.700102 . The distribution itself (as established by its variance) is not very informative but at first sight there would seem to be a great deal of information about the prior distribution itself. This is a feature of some analyses that I have drawn attention to before. See Dawid’s Selection Paradox.

*Figure 4 Prior distribution for θ*

So this is what I think happened. P&B reached for a common default uniform distribution, a beta with parameters 1,1. However, this would yield an expected value of *θ* = 0 . On the other hand, they wished to show that the vaccine efficacy *ψ* was greater than 0.3. They thus asked the question, *what value of θ corresponds to a value of ψ *= 0.3? Substituting in (4) the answer is 0.4117647 or 0.4118 to four decimal places. They explained this in the protocol as follows: ‘The prior is centered at *θ *= 0.4118 (*VE* = 30%) which may be considered pessimistic’.

*Figure 5 Combination of parameters for the prior distribution yielding the required mean. The diagonal light blue line gives the combination of values that will produce the desired mean. The red diamond gives the parameter combination chosen by P&B. The blue circle gives the parameter combination that would also have produced the mean chosen but also the same variance as a beta(1,1). The contour lines show the variance of the distribution as a function of the two parameters.*

Note that the choice of word *centered* is odd. The mean of the distribution is 0.4118 but the distribution is not really *centered* there. Be that as it may, they now had an infinite possible combination of values for ν, ω that would yield an expected value of 0.4118. Note that solving (6) for ν, ω yields

and plugging in μ = 0.4118, ω = 1 gives ν = 0.700102. Possible choices of parameter combinations yielding the same mean are given in Figure 5. An alternative to the beta(0.700102,1) they chose might have been beta(0.78516,1.1215). This would have yielded the same mean but given the equivalent variance to a conventional beta(1,1).

It is also somewhat debatable as to whether *pessimistic* is the right word. The distribution is certainly very uninformative. Note also that just because if the mean value on the scale is transformed to the vaccine efficacy scale it gives a value of 0.30. It does not follow that this is the mean value of the vaccine efficacy. Only medians can be guaranteed to be invariant under transformation. The median of the distribution of *θ* is 0.3716 and this corresponds to a median vaccine efficacy of 0.4088.

# Can you beta Bayesian?

Perhaps unfairly, I could ask, ‘*what has the Bayesian element added to the analysis*?’ A Bayesian might reply, ‘*what advantage does subtracting the Bayesian element bring to the analysis?*’ Nevertheless, the choice of prior distribution here points a problem. It clearly does not reflect what anybody believed about the vaccine efficacy before the trial began. Of course, establishing reasonable prior parameters for any statistical analysis is extremely difficult[2].

On the other hand, if a purely conventional prior is required why not choose beta(1,1) or beta(1/2,1/2), say? I think the 0.3 hypothesised value for vaccine efficacy is a red herring here. What should be of interest to a Bayesian is the posterior probability that the vaccine efficacy is greater than 30%. This does not require that the prior distribution is ‘centred’ on this value.

Of course the point is that provided that the variance of the prior distribution is large enough, the posterior inference is scarcely affected. In any case a Bayesian might reply, ‘if you don’t like the prior distribution choose your own’. To which a diehard frequentist might reply, ‘it is a bit late for choosing prior distributions’.

I take two lessons from this, however. First, where Bayesian analyses are being used we should all try to understand what the prior distribution implies: in what we now ‘believe’ and how data would update such belief[3]. Second, disappointing as this may be to inferential enthusiasts, this sort of thing is not where the action is. The trial was well conceived, designed and conducted and the product was effective. My congratulations to all the scientists involved, including, but not limited to, the statisticians.

# References

- Forbes, C., et al.,
*Statistical distributions*. 2011: John Wiley & Sons. - Senn, S.J.,
*Trying to be precise about vagueness.*Statistics in Medicine, 2007.**26**: p. 1417-1430. - Senn, S.J.,
*You may believe you are a Bayesian but you are probably wrong.*Rationality, Markets and Morals, 2011.**2**: p. 48-66.